课题基金 / 基金详情

Anti-Parasitic Drug Discovery in Epigenetics

Anti-Parasitic Drug Discovery in Epigenetics
表观遗传学中抗寄生虫药物的发现
批准号:
nhmrc : 1074016
负责人:
Prof David Fairlie
金额:
$18.15万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Targeted Calls
财政年份:
2014
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2014-01-01 至 2016-12-31

项目摘要

项目成果

Prof David Fairlie的其他基金

相似基金

相关文献

中文摘要
翻译
寄生虫感染是一个重大的全球健康问题,每年导致100多万人死亡。不幸的是,目前还没有针对任何人类寄生虫感染的许可疫苗,而且在许多情况下,目前的药物存在寄生虫耐药性问题。为了解决这一问题,该项目汇集了来自欧盟、巴西和澳大利亚的顶尖研究人员,以发现和开发针对四种主要人类寄生虫病的新型药物:血吸虫病、利什曼病、恰加斯病和疟疾。
英文摘要
Parasitic infections are a significant global health problem, resulting in more than a million deaths annually. Unfortunately there is no licensed vaccine available for any human parasitic infection, and in many cases current drugs suffer from issues of parasite drug resistance. To address this problem this project brings together leading researchers from the European Union, Brazil, and Australia to discover and develop new types of drugs for four major human parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Super-resolution platform to accelerate biological and molecular research
  • 批准号:
    LE240100134
  • 项目类别:
    Linkage Infrastructure, Equipment and Facilities
  • 资助金额:
    $53.09万
  • 财政年份:
    2024
  • 负责人:
    Prof David Fairlie
  • 依托单位:
Compressing small peptides for cell absorption
  • 批准号:
    DP180103244
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $40.43万
  • 财政年份:
    2018
  • 负责人:
    Prof David Fairlie
  • 依托单位:
Combating infectious diseases by harnessing macrophage functions
  • 批准号:
    nhmrc : GNT1125316
  • 项目类别:
    Project Grants
  • 资助金额:
    $68.82万
  • 财政年份:
    2017
  • 负责人:
    Prof David Fairlie
  • 依托单位:
Modulating Protein-Protein Interactions In Disease
  • 批准号:
    nhmrc : GNT1117017
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $86.39万
  • 财政年份:
    2017
  • 负责人:
    Prof David Fairlie
  • 依托单位:
海外基金